Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | USP7 | Q93009 | 2/20 | 0.37 |
| ▸ | ESRRB | O95718 | 2/20 | 0.36 |
| ▸ | ESRRA | P11474 | 2/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729714 | 0.85 | ESR1 (0.44) | ESR1ESR2S1PR1USP7ESRRB | |
| SCHEMBL5730888 | 0.85 | ESR2 (0.49) | ESR1ESR2S1PR1USP7ESRRB | |
| SCHEMBL5729839 | 0.84 | ESR1 (0.41) | ESR1ESR2S1PR1HSP90AA1USP7 | |
| SCHEMBL5728746 | 0.84 | ESR2 (0.43) | ESR1ESR2S1PR1HSP90AA1USP7 | |
| SCHEMBL5730385 | 0.84 | ESR1 (0.41) | ESR1ESR2S1PR1HSP90AA1USP7 | |
| SCHEMBL5730056 | 0.82 | HSP90AB1 (0.45) | ESR1ESR2S1PR1HSP90AA1USP7 | |
| SCHEMBL5728579 | 0.82 | ESR1 (0.50) | ESR1ESR2HSP90AA1USP7 | |
| SCHEMBL5729197 | 0.81 | ESR1 (0.44) | ESR1ESR2S1PR1USP7ESRRB | |
| SCHEMBL5728955 | 0.81 | HSD17B10 (0.51) | ESR1ESR2S1PR1ESRRBESRRA | |
| SCHEMBL5729293 | 0.81 | S1PR1 (0.42) | ESR1ESR2S1PR1HSP90AA1USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | claimed |
| EP-1102755-B1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-6869969-B2 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6743815-B2 | OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | CHIRON CORPORATION | 2004-05-27 | — | — | US | disclosed |
| US-20030065012-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2003-04-03 | — | — | US | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| US-20010036956-A1 | Estrogen receptor modulators | HUEBNER VERENA D (US) | 2001-11-01 | — | — | US | disclosed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1102755-A1 | SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008001-A1 | SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036956-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885S1PR1 1484/4885 |
| US-20030065012-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885S1PR1 1484/4885 |
| US-20040102498-A1 | Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors | ESR2, GPER1, ESR1 | ESR1 3/4885ESR2 1/4885S1PR1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.